Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 19 - per page Next page
Order by
This invention relates to methods for manipulating the immune system using small interfering RNA (siRNA). Potential applications include the development of organ storage/reperfusion solutions and treatments for a broad range of disease indications. More
Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
A renowned cardiologist and Robarts' Scientist has identified a strong correlation between a polymorphism of a relatively new apolipoprotein gene and severity of hypertiglyceridemia manifestation. More
1,2,4-benzothiadiazine derivatives useful for the treatment of endocrinological system diseases such as hyperinsulinaemia and diabetes. More
Biocompatible and biodegradable nanoparticles designed to encapsulate drug allowing for its absorption and delivery More
"A comprehensive set of samples in various diseases. The resource consists of DNA samples from 16 diseases (Type I diabetes, Type II diabetes, Asthma, Colorectal Cancer, Breast Cancer, Prostate Cancer, Alzheimer's disease, Parkinson's disease... More
This project is based on the finding that a tyrosine kinase highly expressed in the pancreatic Islets of Langerhan is involved in cytokine induced beta-cell death. This tyrosine kinase has been biologically well validated as a novel drug target. More
Aldose reductase inhibitors available for license. More
A simple blood based assay to identify diabetic patients who are likely to develop or have early stage diabetic nephropathy has been developed at King's. This has the potential to be used regularly at diabetic clinics. More
Displaying 1..10 of 19 - per page Next page
Order by
Partnering consultation free of charge
Need competitive intelligence information
Leksir Ltd
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us